228 related articles for article (PubMed ID: 28506979)
1. Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
Pokharel Y; Chinnakondepalli K; Vilain K; Wang K; Mark DB; Davies G; Blazing MA; Giugliano RP; Braunwald E; Cannon CP; Cohen DJ; Magnuson EA
Circ Cardiovasc Qual Outcomes; 2017 May; 10(5):. PubMed ID: 28506979
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
Kato ET; Cannon CP; Blazing MA; Bohula E; Guneri S; White JA; Murphy SA; Park JG; Braunwald E; Giugliano RP
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29151034
[TBL] [Abstract][Full Text] [Related]
3. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
Bohula EA; Wiviott SD; Giugliano RP; Blazing MA; Park JG; Murphy SA; White JA; Mach F; Van de Werf F; Dalby AJ; White HD; Tershakovec AM; Cannon CP; Braunwald E
Circulation; 2017 Dec; 136(25):2440-2450. PubMed ID: 28972004
[TBL] [Abstract][Full Text] [Related]
4. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
Giugliano RP; Cannon CP; Blazing MA; Nicolau JC; Corbalán R; Špinar J; Park JG; White JA; Bohula EA; Braunwald E;
Circulation; 2018 Apr; 137(15):1571-1582. PubMed ID: 29263150
[TBL] [Abstract][Full Text] [Related]
5. Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial.
Murphy SA; Cannon CP; Blazing MA; Giugliano RP; White JA; Lokhnygina Y; Reist C; Im K; Bohula EA; Isaza D; Lopez-Sendon J; Dellborg M; Kher U; Tershakovec AM; Braunwald E
J Am Coll Cardiol; 2016 Feb; 67(4):353-361. PubMed ID: 26821621
[TBL] [Abstract][Full Text] [Related]
6. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White JA; Tershakovec AM; Blazing MA; Braunwald E
Circulation; 2015 Sep; 132(13):1224-33. PubMed ID: 26330412
[TBL] [Abstract][Full Text] [Related]
7. [ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].
Lancellotti P; Pierard LA; Scheen AJ
Rev Med Liege; 2015 Sep; 70(9):450-5. PubMed ID: 26638446
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Simvastatin Plus Ezetimibe for Cardiovascular Prevention in Patients With a History of Acute Coronary Syndrome: Analysis of Results of the IMPROVE-IT Trial.
Almalki ZS; Guo JJ; Alahmari A; Alotaibi N; Thaibah H
Heart Lung Circ; 2018 Jun; 27(6):656-665. PubMed ID: 28716519
[TBL] [Abstract][Full Text] [Related]
9. [IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (studie IMPROVE-IT)].
Špinar J; Špinarová L; Vítovec J
Vnitr Lek; 2014 Dec; 60(12):1095-101. PubMed ID: 25692840
[TBL] [Abstract][Full Text] [Related]
10. Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial.
Giugliano RP; Wiviott SD; Blazing MA; De Ferrari GM; Park JG; Murphy SA; White JA; Tershakovec AM; Cannon CP; Braunwald E
JAMA Cardiol; 2017 May; 2(5):547-555. PubMed ID: 28291866
[TBL] [Abstract][Full Text] [Related]
11. Medication Discontinuation in the IMPROVE-IT Trial.
Navar AM; Roe MT; White JA; Cannon CP; Lokhnygina Y; Newby LK; Giugliano RP; Tershakovec AM; Braunwald E; Califf RM; Blazing MA
Circ Cardiovasc Qual Outcomes; 2019 Jan; 12(1):e005041. PubMed ID: 30630361
[TBL] [Abstract][Full Text] [Related]
12. Reduction of ischemic events in Improved Reduction of Outcomes: Vytorin Efficacy International Trial: Intensive cholesterol lowering or ezetimibe antithrombotic effects?
Pesaro AE; Granger CB; Lopes RD
Am Heart J; 2016 Feb; 172():42-4. PubMed ID: 26856214
[No Abstract] [Full Text] [Related]
13. Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial.
Bach RG; Cannon CP; Giugliano RP; White JA; Lokhnygina Y; Bohula EA; Califf RM; Braunwald E; Blazing MA
JAMA Cardiol; 2019 Sep; 4(9):846-854. PubMed ID: 31314050
[TBL] [Abstract][Full Text] [Related]
14. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial.
Bonaca MP; Gutierrez JA; Cannon C; Giugliano R; Blazing M; Park JG; White J; Tershakovec A; Braunwald E
Lancet Diabetes Endocrinol; 2018 Dec; 6(12):934-943. PubMed ID: 30396865
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes.
Cannon CP; Giugliano RP; Blazing MA; Harrington RA; Peterson JL; Sisk CM; Strony J; Musliner TA; McCabe CH; Veltri E; Braunwald E; Califf RM;
Am Heart J; 2008 Nov; 156(5):826-32. PubMed ID: 19061694
[TBL] [Abstract][Full Text] [Related]
16. Patient Phenotypes, Cardiovascular Risk, and Ezetimibe Treatment in Patients After Acute Coronary Syndromes (from IMPROVE-IT).
Sharma A; Sun JL; Lokhnygina Y; Roe MT; Ahmad T; Desai NR; Blazing MA
Am J Cardiol; 2019 Apr; 123(8):1193-1201. PubMed ID: 30739657
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial.
Qamar A; Giugliano RP; Bohula EA; Park JG; Jarolim P; Murphy SA; Blazing MA; Califf RM; Cannon CP; Braunwald E; Morrow DA
J Am Coll Cardiol; 2019 Aug; 74(8):1057-1068. PubMed ID: 31439215
[TBL] [Abstract][Full Text] [Related]
18. The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial.
Eisen A; Cannon CP; Blazing MA; Bohula EA; Park JG; Murphy SA; White JA; Giugliano RP; Braunwald E;
Eur Heart J; 2016 Dec; 37(48):3576-3584. PubMed ID: 27569841
[TBL] [Abstract][Full Text] [Related]
19. Benefit of Combination Ezetimibe/Simvastatin Among High-Risk Populations: Lessons from the IMPROVE-IT Trial.
Oliver W; Giugliano RP
Curr Atheroscler Rep; 2023 Mar; 25(3):85-93. PubMed ID: 36763180
[TBL] [Abstract][Full Text] [Related]
20. Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention.
Bohula EA; Morrow DA; Giugliano RP; Blazing MA; He P; Park JG; Murphy SA; White JA; Kesaniemi YA; Pedersen TR; Brady AJ; Mitchel Y; Cannon CP; Braunwald E
J Am Coll Cardiol; 2017 Feb; 69(8):911-921. PubMed ID: 28231942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
